Abbott plans to separate its nutrition business into an independent company, which is set to house electrolyte-beverage brand Pedialyte, as well as infant-formula brand Similac, with about $8.5 billion in annual sales. FAQ Q: Why is Abbott splitting its nutrition business? FAQ A: The spin-off aims to focus each company on its core strengths and allow investors to value the businesses separately, with Abbott retaining its medical devices and diagnostics operations while the nutrition unit becomes its own publicly traded entity.
出典: Wall Street Journal US Business · 要約：HeadlinesBriefing